Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 21, Issue 7, Pages 953-955Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458514554056
Keywords
Multiple sclerosis; pregnancy; natalizumab; post-partum; relapses
Categories
Funding
- Bayer-Schering
- Biogen Idec
- Genzyme
- Novartis
- Merck Serono
- Sanofi Aventis
- Teva Pharma
Ask authors/readers for more resources
Objective: Our aim was to evaluate the impact of early redosing of natalizumab after delivery on the risk of post-partum relapses in six women with very active multiple sclerosis (MS). Methods: We undertook a retrospective analysis of data collected prospectively in the Lyon MS Cohort. Results: The annualized relapse rate (ARR) in the year before natalizumab treatment was 4.2 0.4, which decreased to 0.4 +/- 0.6 during the treatment period. The mean time between natalizumab withdrawal and onset of pregnancy was 9 months; one pregnancy was exposed to one infusion. The ARR between natalizumab withdrawal and onset of pregnancy was 1.8 +/- 0.7. Six relapses occurred before onset of pregnancy and seven during pregnancy. Natalizumab was restarted 7.8 days after delivery (between day 2 and 8 for five patients and on day 23 for one). Only one patient, who had restarted natalizumab 2 days after delivery, had a relapse 2 weeks later. The others five patients were relapse free after a mean of 14.2 +/- 9.1 months of follow-up. Conclusion: Despite a high risk of post-partum relapses, early redosing of natalizumab led to a complete disappearance of disease activity in all but one patient. These data suggest that natalizumab could be a good candidate for preventing early post-partum relapses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available